[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.197.114. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
August 1997

The National Institute on Drug Abuse Collaborative Cocaine Treatment StudyRationale and Methods

Author Affiliations

From the Department of Psychiatry, University of Pennsylvania (Drs Crits-Christoph, Siqueland, Luborsky, Woody, Barber, Moras, and Beck and Ms Mercer), and Philadelphia Veterans Hospital (Dr Woody), Philadelphia, Pa; the National Institute on Drug Abuse, Rockville, Md (Drs Blaine and Onken); Brookside Hospital, Nashua, NH (Drs Frank and Butler and Ms Bishop); Gaithersburg, Md (Dr Muenz); Western Psychiatric Institute and Clinic, University ofPittsburgh, Pittsburgh, Pa (Dr Thase, Mr Daley, and Ms Lis); and Harvard Medical School and McLean Hospital (Drs Weiss, Najavits, and Griffin) or Massachusetts General Hospital (Dr Gastfriend), Boston, Mass. A complete list of the members of the National Institute on Drug Abuse Collaborative Cocaine Treatment Study Group appears on page 722.

Arch Gen Psychiatry. 1997;54(8):721-726. doi:10.1001/archpsyc.1997.01830200053007
Abstract

The National Institute on Drug Abuse Collaborative Cocaine Treatment Study is a large, multisite psychotherapy clinical trial for outpatients who meet the DSM-IV criteria for cocaine dependence. For 480 randomized patients, the outcomes of 4 treatments are compared for an 18-month period. All treatments include group drug counseling. One treatment also adds cognitive therapy, one adds supportive-expressive psychodynamic therapy, and one adds individual drug counseling; one consists of group drug counseling alone. In addition, 2 specific interaction hypotheses, one involving psychiatric severity and the other involving degree of antisocial personality characteristics, are being tested. This article describes the main aims of the project, the background and rationale for the study design, the rationale for the choice of treatments and patient population, and a brief description of the research plan.

×